- Home
- MNPR vs FINW Comparison
MNPR vs FINW Comparison
Compare MNPR & FINW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- FINW
- Stock Information
- Founded
- MNPR 2014
- FINW 1999
- Country
- MNPR United States
- FINW United States
- Employees
- MNPR N/A
- FINW N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- FINW Commercial Banks
- Sector
- MNPR Health Care
- FINW Finance
- Exchange
- MNPR Nasdaq
- FINW Nasdaq
- Market Cap
- MNPR 248.8M
- FINW 207.1M
- IPO Year
- MNPR 2019
- FINW 2021
- Fundamental
- Price
- MNPR $35.71
- FINW $18.51
- Analyst Decision
- MNPR Strong Buy
- FINW Buy
- Analyst Count
- MNPR 7
- FINW 4
- Target Price
- MNPR $62.00
- FINW $20.75
- AVG Volume (30 Days)
- MNPR 20.7K
- FINW 19.2K
- Earning Date
- MNPR 08-12-2025
- FINW 07-24-2025
- Dividend Yield
- MNPR N/A
- FINW N/A
- EPS Growth
- MNPR N/A
- FINW N/A
- EPS
- MNPR N/A
- FINW 0.96
- Revenue
- MNPR N/A
- FINW $74,999,000.00
- Revenue This Year
- MNPR N/A
- FINW $50.70
- Revenue Next Year
- MNPR N/A
- FINW $22.82
- P/E Ratio
- MNPR N/A
- FINW $19.26
- Revenue Growth
- MNPR N/A
- FINW 10.21
- 52 Week Low
- MNPR $2.15
- FINW $11.92
- 52 Week High
- MNPR $54.30
- FINW $20.94
- Technical
- Relative Strength Index (RSI)
- MNPR 43.81
- FINW 63.63
- Support Level
- MNPR $30.51
- FINW $17.66
- Resistance Level
- MNPR $36.51
- FINW $19.64
- Average True Range (ATR)
- MNPR 3.33
- FINW 0.63
- MACD
- MNPR -0.95
- FINW 0.02
- Stochastic Oscillator
- MNPR 37.55
- FINW 57.91
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About FINW FinWise Bancorp
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.